GU Cancers Symposium: Cytoreductive Nephrectomy for Metastatic Papillary Kidney Cancer
Patients with metastatic papillary renal cell carcinoma may benefit from cytoreductive nephrectomy, according to a new study led by Jeffrey Graham, MD, of the Tom Baker Cancer Centre at the University of Calgary, Alberta, Canada. These results, which were presented at the 2018 Genitourinary Cancers Symposium in San Francisco (Abstract 581), seem to corroborate with the clear cell literature, Dr. Graham and colleagues suggest.
Evidence of the treatment’s success among patients with metastatic renal cell carcinoma has been seen, but its role in those with papillary histology has been unclear. So, the investigators used the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) to conduct a retrospective analysis of 353 patients with papillary metastatic renal cell carcinoma who were treated with or without cytoreductive nephrectomy. Within the patient pool, 75 individuals were identified with a component of clear cell histology.
Patients who underwent cytoreductive nephrectomy were more likely to be younger, have a better Karnofsky performance status, and have sarcomatoid histology. With a median follow-up of 57.1 months, median overall survival in patients treated with cytoreductive nephrectomy was 16.3 months versus 8.6 months in those not treated with the surgery. After adjusting for individual IMDC risk factors, the investigators reported a hazard ratio of death for cytoreductive nephrectomy of 0.62.